drug
AUBAGIO
updated 3mo agoby Sanofi-Aventis US LLC
community read0 votes
🐶 often sniffed alongside
top 7- tagApproval56 co-mentions · 14 sources
- drugteriflunomide29 co-mentions · 15 sources
- company$SNYSanofi28 co-mentions · 14 sources
- company$SNYNFSanofi28 co-mentions · 14 sources
- tagSmall Molecule28 co-mentions · 14 sources
- companyGlenmark Pharmaceuticals Ltd3 co-mentions · 1 sources
- tagRecall1 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying AUBAGIO
- —A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
- phase3Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
- phase3Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
- phase3Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
- phase3Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
- phase3A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
- phase3A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
- phase4Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that